C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid
Plus the initial dosing of Enanta and Avencell's Clinical Trials
Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation
Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates
Parallel Bio's Expansion into Therapeutics, and We're Looking Out for More Potential Cash Flow Challenges -Watertown Bio News RoundUp
Plus, where key opinion leaders see Watertown's biotech sector heading.
Watertown's Emerging Rare Blood Disorder Therapy Cluster, Warning Signs For Werewolf, and Fallout for Disc Medicines-Watertown Bio News RoundUp
Join us next week in Charting Watertown’s Life Science Future
An FDA Rejection, A Big Pharma Purchase, and Charting Watertown's Life Science Future -Watertown Bio News RoundUp
Plus another $10 million in VC raised, Souffle inks a partnership with Bayer, and more
All About Watertown's VC Funding
2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more
What we're looking forward to in 2026
Neumora's positive clinical data , new tenants at the Arsenal, and more
Kymera and Psithera's Funding Haul
A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.
Cultivarium's Next Steps
Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more
Labshares Expanding to Watertown
Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more
Welcome to Watertown Bio
Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.